KYMR Kymera Therapeutics Inc.

46.64
-1.39  -3%
Previous Close 48.03
Open 48.27
52 Week Low 25.43
52 Week High 53.49
Market Cap $2,073,565,008
Shares 44,458,941
Float 32,448,868
Enterprise Value $1,859,336,936
Volume 248,217
Av. Daily Volume 112,870
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
IRAKIMiD program
Diffuse large B-cell lymphoma (DLBCL)
Phase 1
Phase 1
Phase 1 trial to commence 2H 2021.
STAT3 program
Oncology
Phase 1
Phase 1
Phase 1 trial to be initiated 2H 2021.
KT-474
Hidradenitis suppurativa / atopic dermatitis
Phase 1
Phase 1
Phase 1 trial to be initiated 1H 2021.

Latest News

  1. WATERTOWN, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system, today announced Nello Mainolfi, Co-Founder, President and CEO and Jared Gollob, Chief Medical Officer of Kymera Therapeutics, will present at the Piper Sandler 32nd Annual Healthcare Conference being held virtually from December 1 to December 3, 2020.

    A webcast of the pre-recorded fireside chat presentation has been made available ahead of the conference and can be accessed by clicking here and found under "Events and Presentations" in…

    WATERTOWN, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system, today announced Nello Mainolfi, Co-Founder, President and CEO and Jared Gollob, Chief Medical Officer of Kymera Therapeutics, will present at the Piper Sandler 32nd Annual Healthcare Conference being held virtually from December 1 to December 3, 2020.

    A webcast of the pre-recorded fireside chat presentation has been made available ahead of the conference and can be accessed by clicking here and found under "Events and Presentations" in the Investors section of the Company's website at www.kymeratx.com. The webcast will remain available for 90 days.

    About Kymera Therapeutics

    Kymera Therapeutics is a biopharmaceutical company focused on a transformative new approach to address previously intractable disease targets. Kymera is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. Kymera's initial programs target IRAK4, IRAKIMiD and STAT3 within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies and solid tumors. For more information, visit www.kymeratx.com.

    Contact:



    Bruce Jacobs

    Chief Financial Officer

    +1 857.285.5300

    Christopher F. Brinzey

    Westwicke, an ICR Company for Kymera Therapeutics



    +1 339.970.2843

    Lissette L. Steele

    Verge Scientific Communications for Kymera Therapeutics



    +1 202.930.4762



    Primary Logo

    View Full Article Hide Full Article
  2. WATERTOWN, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system, today announced Nello Mainolfi, Co-Founder, President and CEO of Kymera Therapeutics, will present at the Stifel 2020 Virtual Healthcare Conference at 8:00 a.m. ET on Tuesday, November 17, 2020.

    A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors section of the Company's website at www.kymeratx.com. An archived webcast recording of the presentation will be available on the website for approximately…

    WATERTOWN, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system, today announced Nello Mainolfi, Co-Founder, President and CEO of Kymera Therapeutics, will present at the Stifel 2020 Virtual Healthcare Conference at 8:00 a.m. ET on Tuesday, November 17, 2020.

    A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors section of the Company's website at www.kymeratx.com. An archived webcast recording of the presentation will be available on the website for approximately 90 days.

    About Kymera Therapeutics

    Kymera Therapeutics is a biopharmaceutical company focused on a transformative new approach to address previously intractable disease targets. Kymera is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. Kymera's initial programs target IRAK4, IRAKIMiD and STAT3 within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies and solid tumors. For more information, visit www.kymeratx.com.

    Contact:



    Bruce Jacobs

    Chief Financial Officer

    +1 857.285.5300

    Christopher F. Brinzey

    Westwicke, an ICR Company for Kymera Therapeutics



    +1 339.970.2843

    Lissette L. Steele

    Verge Scientific Communications for Kymera Therapeutics



    +1 202.930.4762

    Primary Logo

    View Full Article Hide Full Article
  3. Well positioned to advance a leading pipeline of targeted protein degradation medicines with recent completion of upsized initial public offering and strategic collaboration with Sanofi

    Reported positive interim results from non-interventional study of KT-474 (IRAK4 degrader) in HS patients and declared KT-413 (IRAKIMiD degrader) as a development candidate and initiated IND enabling activities

    WATERTOWN, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader therapeutics, today reported financial results for the third quarter ended September 30, 2020 and provided a business update…

    Well positioned to advance a leading pipeline of targeted protein degradation medicines with recent completion of upsized initial public offering and strategic collaboration with Sanofi

    Reported positive interim results from non-interventional study of KT-474 (IRAK4 degrader) in HS patients and declared KT-413 (IRAKIMiD degrader) as a development candidate and initiated IND enabling activities

    WATERTOWN, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader therapeutics, today reported financial results for the third quarter ended September 30, 2020 and provided a business update.

    "Kymera has made significant progress since the company was founded just over four years ago," commented Nello Mainolfi, co-founder, president and CEO of Kymera. "Our investment in our Pegasus™ discovery engine is delivering a unique pipeline of potential first-in-class protein degrader medicines allowing us to address diseases in a completely novel way. Rather than inhibiting protein function we are leveraging the body's natural recycling machinery to degrade disease-causing proteins. We have made great strides to accelerate the path to becoming a fully integrated biotech, including establishing strategic partnerships with Sanofi and Vertex Pharmaceuticals that further extend the potential impact of our protein degrader therapies to even more patients and diseases. With a successful IPO completed, our cash runway extends into 2025. We are well positioned to advance multiple programs in oncology and immune-inflammatory diseases, with our first program expected to enter the clinic in the first half of 2021."

    Quarterly Highlights

    • Completed initial public offering (IPO). In August 2020, Kymera closed an upsized IPO of 9,987,520 of its common shares, including the exercise in full of the underwriters' option to purchase an additional 1,302,720 common shares, at a public offering price of $20.00 per share. Concurrent with the IPO, Kymera announced the sale of 676,354 common shares at the public offering price per share in a private placement to Vertex Pharmaceuticals Incorporated, an existing investor. Total gross proceeds to Kymera, before deducting underwriting commissions and offering expenses, were approximately $213.3 million.



    • Announced multi-program strategic collaboration with Sanofi to develop and commercialize first-in-class protein degrader therapies. Under the terms of the collaboration, signed in July 2020, Kymera received a $150 million upfront payment and can earn more than $2 billion in potential development, regulatory and sales milestones, as well as future royalties on its IRAK4 degraders in immunology and inflammation indications, and a second undisclosed target. The Company retains the ability to participate equally in U.S. development and commercialization of both programs and also retains full rights of its IRAK4 degraders in oncology and immuno-oncology.



    • Presented positive interim results from a non-interventional study on IRAK4 at the 5th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) virtual conference. IRAK4 levels were shown to be higher in active hidradenitis suppurativa (HS) lesions compared to unaffected skin and in circulating monocytes. Additionally, ex vivo treatment of blood from HS patients with its lead IRAK4 degrader, KT-474, lowered IRAK4 levels across all peripheral blood mononuclear cell subsets. These results support clinical development of KT-474 in HS and other IL-1R/TLR-driven immune-inflammatory diseases. A link to the poster can be found here.



    • Expanded organization with the addition of Chief Scientific Officer and two new appointees to the Board of Directors. Recruiting top talent remains a key organizational priority to meet corporate objectives. In August, the Company announced the appointment of Dr. Richard Chesworth as Chief Scientific Officer. Dr. Chesworth brings a proven track record in biopharmaceuticals having contributed to the research and development of several investigational or approved drugs. In September, the Company announced the appointment of two biopharmaceutical veterans, Jeff Albers and Pamela Esposito, to expand its Board of Directors and support the Company's strategic direction and mission to realize the promise of protein degrader therapies for patients.

    Program Updates and Milestones

    Kymera is discovering and developing novel small molecule therapeutics that selectively degrade disease causing proteins by harnessing the body's own natural protein degradation system.

    • IRAK4 degrader for IL-1R/TLR-driven immune-inflammatory diseases. KT-474, a highly active and selective, orally bioavailable IRAK4 degrader, is being developed for the treatment of IL-1R/TLR-driven immune-inflammatory diseases with high unmet medical need. These diseases include hidradenitis suppurativa, as well as atopic dermatitis and rheumatoid arthritis. Kymera expects to file an Investigational New Drug (IND) application for KT-474 and, if cleared, begin a Phase 1 clinical trial in the first half of 2021.



    • IRAKIMiD degrader for MYD88-mutant lymphoma.  IRAKIMiDs are IRAK4 degraders with a unique profile that combines the activity of IRAK4 degradation and IMiDs in a single agent to address both the IL-1R/TLR and Type 1 IFN pathways synergistically and generate broad activity against MYD88-mutant B cell lymphomas. In the third quarter of 2020, Kymera declared KT-413 as a development candidate and initiated IND enabling activities. Kymera expects to file an IND and, if cleared, to begin a Phase 1 clinical trial in the second half of 2021. KT-413's strong antitumor activity allows for intermittent dosing, consistent with initial plans for an intravenous formulation due to current standard-of-care and clinical entry point in MYD88-mutated diffuse large B cell lymphoma (DLBCL). As KT-413 is equally efficacious when dosed orally, development of an oral formulation is also being evaluated. Pre-clinical characterization of KT-413 will be presented at the American Society of Hematology annual meeting in December 2020. A link to the press release announcing the abstracts can be found here.



    • STAT3 degrader for oncologic and immune-inflammatory diseases. The STAT3 program is being developed for the treatment of hematological malignancies and solid tumors, as well as autoimmune diseases and fibrosis. STAT3 is a transcription factor activated through a variety of different cytokine and growth factor receptors via janus kinases (JAKs), as well as through oncogenic fusion proteins and mutations in STAT3 itself. Kymera continues to expect to file an IND and, if cleared, begin a Phase 1 clinical trial in the second half of 2021 for its lead STAT3 degrader. Pre-clinical data will be presented at the American Society of Hematology annual meeting in December 2020. A link to the press release announcing the abstracts can be found here.

    Third Quarter 2020 Financial Results

    Collaboration Revenues: Total revenues for the quarter ended September 30, 2020 were $14.5 million, compared to $1.0 million for same period in 2019. Collaboration revenue includes revenue from our Sanofi and Vertex collaborations in 2020, and Vertex in 2019.

    Research and Development Expenses: Research and development expenses were $15.8 million for the quarter ended September 30, 2020, compared to $11.3 million for the same period in 2019. This increase was primarily due to higher direct expenses related to IND-enabling studies for our IRAK programs, lead optimization activities for our STAT3 programs, investment in our platform, exploratory programs, and Vertex collaboration as well as an increase in occupancy and related costs due to continued growth in the research and development organization

    General and Administrative Expenses: General and Administrative expenses were $6.8 million for the quarter ended September 30, 2020, compared to $1.5 million for the same period in 2019. This increase was primarily due to increases in legal and professional service fees in support of our growth and an increase in personnel, facility and other expenses stemming from an increase in headcount to support our operations as a public company.



    Net Loss: Net loss for the quarter ended September 30, 2020 was $8.0 million, or $0.39 per share, compared to a net loss of $11.4 million, or $6.54 per share, for the same period in 2019.

    Cash and Cash Equivalents: As of September 30, 2020, Kymera had approximately $481.3 million in cash, cash equivalents and investments. Kymera expects that its current cash, cash equivalents, and investments as of September 30, 2020, excluding any future potential milestones from collaborations, will enable the Company to fund its operational plans into 2025.

    About Kymera Therapeutics

    Kymera Therapeutics is a biopharmaceutical company focused on a transformative new approach to address previously intractable disease targets. Kymera is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus™ targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. Kymera's initial programs target IRAK4, IRAKIMiD and STAT3 within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies and solid tumors. For more information, visit www.kymeratx.com.

    About Pegasus™

    Pegasus™ is Kymera Therapeutics' proprietary protein degradation platform, created by its team of experienced drug hunters to improve the effectiveness of targeted protein degradation and generate a pipeline of novel therapeutics for previously undruggable diseases. The platform consists of informatics driven target identification, novel E3 ligases, proprietary ternary complex predictive modeling capabilities, and degradation tools.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding its: strategy, expectations regarding cash runway and strategy, business plans and focus; plans and timelines for the clinical development of Kymera Therapeutics' product candidates, therapeutic potential and clinical benefits thereof; growth as a company; expectations regarding future interactions with the U.S. Food and Drug Administration (FDA), including timelines for filing INDs; and uses of capital. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of COVID-19 on countries or regions in which we have operations or do business, as well as on the timing and anticipated results of our current preclinical studies and future clinical trials, strategy and future operations; the delay of any current preclinical studies or future clinical trials or the development of Kymera Therapeutics' drug candidates; the risk that the results of current preclinical studies may not be predictive of future results in connection with future clinical trials; Kymera Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of the Company's planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property.  These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" included in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, as well as discussions of potential risks, uncertainties, and other important factors in Kymera Therapeutics' subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Kymera Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Kymera Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

    Investors:



    Bruce Jacobs

    Chief Financial Officer

    +1 857.285.5314

    Christopher F. Brinzey

    Westwicke, an ICR Company for Kymera Therapeutics



    +1 339.970.2843

    Media:

    Lissette L. Steele

    Verge Scientific Communications for Kymera Therapeutics

    KYMERA THERAPEUTICS, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    Three and Nine Months Ended September 30, 2020 and 2019

    (In thousands, except for share and per share amounts)

    (Unaudited)

      Three Months Ended

    September 30,
      Nine Months Ended

    September 30,
     
      2020   2019   2020   2019  
                 
    Collaboration Revenue—from related parties $14,533   $950   $21,249   $1,101  
                     
    Operating expenses:                
    Research and development $15,778   $11,310   $41,713   $26,072  
    General and administrative  6,838    1,501    13,058    5,451  
    Total operating expenses  22,616    12,811    54,771    31,523  
    Loss from operations  (8,083)   (11,861   (33,522)   (30,422) 
    Other income (expense):                
    Interest Income  125    445    702    705  
    Interest Expense  (29   (4)   (88   (16 
    Total other income:  97    441    614    689  
    Net loss $(7,986)  $(11,420)  $(32,908)  $(29,733) 
    Deemed dividend from exchange of convertible preferred stock          (9,050)     
    Net loss attributable to common stockholders $(7,986)  $(11,420)  $(41,958)  $(29,733) 
    Net loss per share attributable to common stockholders, basic and diluted $(0.39)  $(6.54)  $(5.11)  $(18.15) 
    Weighted average common stocks outstanding, basic and diluted  20,677,392    1,745,404    8,211,003    1,638,579  





    KYMERA THERAPEUTICS, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (In thousands, except for share and per share amounts)

    (Unaudited)

      September 30,

    2020
      December 31,

    2019
     
    Assets        
    Cash, cash equivalents and marketable securities $481,305  $91,957  
    Property and equipment, net  10,984   3,794  
    Other assets  15,072   20,951  
         Total assets $507,361  $116,702  
    Liabilities and Stockholders' Equity (Deficit        
    Deferred revenue $182,319  $52,991  
    Other liabilities  30,357   29,037  
    Total liabilities  212,676   82,028  
    Preferred stock   -   109,080  
    Total stockholders' equity (deficit)  294,685   (74,406) 
    Total liabilities, preferred stock and stockholders' equity (deficit) $507,361  $116,702  

     

    Primary Logo

    View Full Article Hide Full Article
  4. WATERTOWN, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader therapeutics, today announced the company will present new preclinical data for its IRAKIMiD and STAT3 degrader programs at the 62nd American Society of Hematology (ASH) Annual Meeting taking place virtually from Dec. 5-8, 2020.

    "We are excited to share for the first time preclinical data of our IRAKIMiD development candidate KT-413 (formerly KTX-120) as well as an expanded preclinical investigation of our STAT3 degrader program which have allowed us to uncover important insights into their therapeutic potential across a variety of hematologic…

    WATERTOWN, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader therapeutics, today announced the company will present new preclinical data for its IRAKIMiD and STAT3 degrader programs at the 62nd American Society of Hematology (ASH) Annual Meeting taking place virtually from Dec. 5-8, 2020.

    "We are excited to share for the first time preclinical data of our IRAKIMiD development candidate KT-413 (formerly KTX-120) as well as an expanded preclinical investigation of our STAT3 degrader program which have allowed us to uncover important insights into their therapeutic potential across a variety of hematologic cancers," said Jared Gollob, MD, Chief Medical Officer, Kymera Therapeutics. "The results also establish the potential for intermittent dosing schedules for both programs as we guide their advancement into the clinic next year." 

    IRAKIMiD Program

    ABSTRACT #2088, "KTX-120, a Novel IRAKIMiD Degrader of IRAK4 and IMiD substrates shows Preferential Activity and Induces Regressions in MYD88-Mutant DLBCL CDX and PDX models," presented by Duncan H. Walker, PhD, Vice President of Oncology at Kymera Therapeutics. Poster Session II: Sunday, Dec. 6th (7:00 AM - 3:30 PM PT).

    ABSTRACT #3013, "Targeting MYD88-Mutant DLBCL with IRAKIMiDs: A Comparison to IRAK4 Kinase Inhibition and Evaluation of Synergy with Rational Combinations," presented by Jennifer K. Lue, MD of Columbia University Irving Medical Center. Poster Session III: Monday, Dec. 7th (7:00 AM - 3:30 PM PT).

    Data to be presented show:

    • Deep and Sustained Tumor Regressions with Intermittent Dosing in MYD88-mutant DLBCL: KT-413 was well tolerated and exhibited potent and sustained antitumor activity in multiple MYD88-mutant mouse CDX and PDX models of DLBCL across a range of both PO and IV intermittent dosing schedules.
    • Preferential Anti-Tumor Activity in MYD88-mutant DLBCL Irrespective of Co-Mutations: KT-413 anti-tumor activity was specific to MYD88-mutant cell lines (relative to WT cell lines) and was independent of a variety of common co-mutations that further activate the NF-kB and IRF4 pathways.
    • Superiority to IMiDs and IRAK4 Kinase Inhibitor: In MYD88-mutant models of DLBCL, IRAKIMiDs showed superior cell killing compared to either IMiDs or an IRAK4 kinase inhibitor alone.
    • Synergistic Combination Potential: Rational combinations of IRAKIMiDs with either BCL2, BTK, or PI3K inhibitors showed synergistic in vitro activity in MYD88-mutant DLBCL.

    STAT3 Program

    ABSTRACT #2090, "Mechanisms of the Anti-tumor Activity of STAT3 Degraders in Lymphoma," presented by Haojing Rong, PhD, Vice President of Pre-Clinical Development. Poster Session II: Sunday, Dec. 6th (7:00 AM - 3:30 PM PT).

    Data to be presented show:

    • Tumor Regressions in STAT3-dependent ALK+ ALCL with Intermittent Dosing: Weekly dosing with KTX-201 achieved complete tumor regressions at doses that lowered tumor levels of STAT3 by >90% and maintained that lowering for up to 4 days post-dose.
    • Antitumor Mechanism of Action: Proteomics showed that STAT3 degradation in vitro by KTX-201 in ALK+ ALCL was associated with inhibition of cytokine signaling, G1 cell cycle arrest and induction of apoptosis.

    These findings build on results reported at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, which highlighted the potent anti-tumor effects of Kymera's selective IRAKIMiD and STAT3 degraders in multiple animal models of cancer.

    About Kymera Therapeutics

    Kymera Therapeutics is a biopharmaceutical company focused on a transformative new approach to address previously intractable disease targets. Kymera is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. Kymera's initial programs target IRAK4, IRAKIMiD and STAT3 within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies and solid tumors. For more information, visit www.kymeratx.com.

    About Pegasus™

    Pegasus™ is Kymera Therapeutics' proprietary protein degradation platform, created by its team of experienced drug hunters to improve the effectiveness of targeted protein degradation and generate a pipeline of novel therapeutics for previously undruggable diseases. The platform consists of informatics driven target identification, novel E3 ligases, proprietary ternary complex predictive modeling capabilities, and degradation tools.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding its: strategy, business plans and objectives for the IRAKIMiD and STAT3 degrader programs; and plans and timelines for the clinical development of Kymera Therapeutics' product candidates, including the therapeutic potential and clinical benefits thereof. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of COVID-19 on countries or regions in which we have operations or do business, as well as on the timing and anticipated results of our current preclinical studies and future clinical trials, strategy and future operations; the delay of any current preclinical studies or future clinical trials or the development of Kymera Therapeutics' drug candidates; the risk that the results of current preclinical studies may not be predictive of future results in connection with future clinical trials; Kymera Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of the Company's planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property.  These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the Quarterly Report on Form 10-Q for the period ended Septmeber 30, 2020, filed on November 5, 2020, as well as discussions of potential risks, uncertainties, and other important factors in Kymera Therapeutics' subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Kymera Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Kymera Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

    Contact:



    Bruce Jacobs

    Chief Financial Officer

    (857) 285-5314

    Christopher F. Brinzey

    Westwicke, an ICR Company for Kymera Therapeutics



    (339) 970-2843

    Lissette L. Steele

    Verge Scientific Communications for Kymera Therapeutics



    +1 202.930.4762

    Primary Logo

    View Full Article Hide Full Article
  5. WATERTOWN, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader therapeutics, will share two key presentations at the 3rd Annual Targeted Protein Degradation Summit on Oct. 14 and 15. Kymera Co-Founder, President and CEO, Nello Mainolfi, PhD, will deliver a keynote presentation, "Targeted Protein Degradation Beyond Oncology," and share recent data related to the company's IRAK4 program including findings from the company's non-interventional trial in hidradenitis suppurativa (HS) patients. Haojing Rong, PhD, Vice President of Pre-Clinical Development, will present on Kymera's efforts to elucidate…

    WATERTOWN, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader therapeutics, will share two key presentations at the 3rd Annual Targeted Protein Degradation Summit on Oct. 14 and 15. Kymera Co-Founder, President and CEO, Nello Mainolfi, PhD, will deliver a keynote presentation, "Targeted Protein Degradation Beyond Oncology," and share recent data related to the company's IRAK4 program including findings from the company's non-interventional trial in hidradenitis suppurativa (HS) patients. Haojing Rong, PhD, Vice President of Pre-Clinical Development, will present on Kymera's efforts to elucidate preclinical pharmacokinetic/pharmacodynamic relationships to predict clinical PK/PD.

    "Targeted Protein Degradation: Beyond Oncology" (Keynote Plenary Session), will be presented by Dr. Mainolfi, PhD, Co-Founder, President and Chief Executive Officer of Kymera on Oct. 15 at 9:00 AM ET.

    Dr. Mainolfi will present on the company's Pegasus platform and approach to target selection, focusing on the IRAK4 degrader program in immunology/inflammation, and will present interim findings from a non-interventional trial evaluating IRAK4 expression and the activity of Kymera's lead IRAK4 protein degrader KT-474 in hidradenitis suppurativa (HS) and atopic dermatitis (AD).

    "Through pre-clinical research and now a non-interventional trial evaluating IRAK4 expression and IRAK4 degrader activity in HS and AD patients, Kymera has continued to demonstrate the potential of IRAK4 degraders to treat a range of diseases beyond oncology. We look forward to sharing our findings and approach with our colleagues, and more broadly, to highlight the importance of understanding PKPD across different cell types responsible for inflammatory processes." said Dr. Mainolfi, PhD, Co-Founder, President and Chief Executive Officer of Kymera.

    Data were first shared during a poster presentation at the 5th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) on October 9th, 2020. Key findings presented demonstrated that IRAK4 levels were higher in diseased compared to unaffected skin, further supporting the relevance of the IRAK4 signaling pathway in HS. The study also showed that ex vivo incubation of HS blood with Kymera's protein degrader KT-474 reduced IRAK4 to a level approaching the lower limits of detection across all PBMC subsets.

    "PK/PD Relationship in Targeted Protein Degradation (TPD)" (Virtual Poster Presentation) will be presented by Dr. Rong, PhD, Vice President of Pre-Clinical Development on Oct. 14 at 4:00 PM ET.

    Kymera's second presentation will center on the critical need to understand key principles of PK/PD relationships in preclinical species for this new modality and use these learnings to establish optimal dosing paradigms and schedules in preclinical species and eventually to predict human PK/PD and active doses as accurately as possible.

    "Our quantitative system pharmacology modeling is an essential tool to dissect the PK/PD interplay in vivo and to predict dosing in humans," said Dr. Rong, PhD, Vice President of Preclinical Development at Kymera. "At Kymera, we view preclinical investigation of the PKPD relationships across cell and tissue types as an opportunity to glean essential information to guide each step of our drug development process."

    About Kymera Therapeutics

    Kymera Therapeutics is a biopharmaceutical company focused on a transformative new approach to address previously intractable disease targets. Kymera is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. Kymera's initial programs target IRAK4, IRAKIMiD and STAT3 within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies and solid tumors. For more information, visit www.kymeratx.com.

    About Pegasus™

    Pegasus™ is Kymera Therapeutics' proprietary protein degradation platform, created by its team of experienced drug hunters to improve the effectiveness of targeted protein degradation and generate a pipeline of novel therapeutics for previously undruggable diseases. The platform consists of informatics driven target identification, novel E3 ligases, proprietary ternary complex predictive modeling capabilities, and degradation tools.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding its: strategy, business plans and focus; plans and timelines for the clinical development of Kymera Therapeutics' product candidates, therapeutic potential and clinical benefits thereof; growth as a company; expectations regarding future interactions with the U.S. Food and Drug Administration (FDA); and uses of capital. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of COVID-19 on countries or regions in which we have operations or do business, as well as on the timing and anticipated results of our current preclinical studies and future clinical trials, strategy and future operations; the delay of any current preclinical studies or future clinical trials or the development of Kymera Therapeutics' drug candidates; the risk that the results of current preclinical studies may not be predictive of future results in connection with future clinical trials; Kymera Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of the Company's planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property.  These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in  the final prospectus dated August 20, 2020 and filed pursuant to Rule 424(b) under the Securities of 1933, as amended, with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in Kymera Therapeutics' subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Kymera Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Kymera Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

    Contact:





    Bruce Jacobs

    Chief Financial Officer

    (857) 285-5314



    Christopher F. Brinzey

    Westwicke, an ICR Company for Kymera Therapeutics



    (339) 970-2843







    Lissette L. Steele

    Verge Scientific Communications for Kymera Therapeutics



    +1 202.930.4762

    Primary Logo

    View Full Article Hide Full Article
View All Kymera Therapeutics Inc. News